ACE-011
| Celgene Corporation
and
Acceleron Pharma
| Protein based on activin receptor IIA that works by both inhibiting bone loss and stimulating bone formation.
|
AMG162
(denosumab,
osteoprotegerin, OPG)
| Amgen | For treatment of patients with bone metastases due to advanced solid tumors or multiple myeloma and for the treatment of patients with relapsed or plateau-phase multiple myeloma. |
Aplidin® | PharmaMar, SA | For relapsed or refractory myeloma |
AP23573 | Ariad Pharmaceuticals | Rapamycin analog for refractory or recurrent malignancy, including myeloma and lymphoma. |
Atiprimod | Calisto
Pharmaceuticals | For patients with refractory multiple myeloma who have failed two or more prior therapies. |
ATN-224
| Attenuon, LLC
| Given in combination with Velcade to patients who are relapsed from or refractory to Velcade. .
|
Avastin™
(bevacizumab,
rhuMAb-VEGF)
| Genentech Inc. | Given in combination with Velcade to patients with relapsed/refractory mm. |
azacitidine (Vidaza®)
| Investigator initiated | Drug previously approved in US for MDS being used in clinical trial for rel/ref mm in Melbourne, Australia. |
Bexxar
(Iodine I 131 tositumomab)
| GlaxoSmithKline,
U of Michigan
| Radioactive antibody to CD20-expressing cells for patients with newly diagnosed or relapsed multiple myeloma.
|
Campath-1H
(alemtuzumab,
monoclonal
antibody CD52)
| NCI and Fred Hutchinson Cancer Research Institute | Used before allo transplant to prevent GVHD |
carfilzomib (PR-171)
| Proteolix | Study of carfilzomib in relapsed and refractory mm at St. Vincent’s Hospital in NY. |
CC4047 (formerly “Actimid”)
(pomalidomide)
| The study is being conducted by Dr. Martha Lacy at the Mayo Clinic in Rochester, MN. If you are interested, please contact Dr. Lacy’s study ass't, Melanie Thompson, at 507-266-0733. | For patients with relapsed disease who have had 3 or fewer previous regimens. |
Celebrex
(celecoxib)
| National Cancer Institute | Prevention study for patients with MGUS or smoldering myeloma. |
CG53135-05
| CuraGen
| For treatment of oral mucositis in patients undergoing autologous stem cell transplant
|
CNTO 328 | Centocor | Given in combination with Velcade to patients with relapsed/refractory mm. |
CTY997
| Cytopia Limited | Prospective, single-arm, open-label trial of a vascular-disrupting agent in the treatment of relapsed/refractory mm. |
dasatinib (Sprycel™; BMS-354825)
| Bristol-Myers Squibb | BCR/ABL and Src tyrosine kinase inhibitor for treatment of relapsed or plateau phase MM. |
Dendritic Cell
Vaccine
| Arkansas Cancer Research Center | Autologous dendritic cells for high-risk mutiple myeloma. |
DLI (donor
lymphocyte
infusion)
| National Cancer Institute | For relapse following allo transplant. |
eltrombopag
(SB-497115; "115")
| GlaxoSmithKline
| Small-molecule drug that mimics the activity of thrombopoietin (TPO) to promote growth and production of platelets.
|
enzastaurin | Eli Lilly | A Study for Patients Who Have Previously Been Treated in Waldenstrom’s Macroglobulinemia or Multiple Myeloma
Site info: Dana-Farber Cancer Institute, Boston, MA, Dr. Irene Ghobrial, PI, 617-632-4198; Nantes, France and Paris, France. |
Erbitux,
cetuximab
| Eli Lilly
| EMMA-1 (Erbitux for Multiple Myeloma); cetuximab +/- dex for patients with refractory mm stage II or III or relapsed disease after at least one line of treatment.
Site Info: University of Cologne, Germany
|
Ethyol®
(amifostine)
| MedImmune, Inc. | Cytoprotective agent to allow higher-dose melphalan in high-dose therapy with auto-transplant.
|
Gallium
Maltolate | Titan Pharmaceuticals | Treatment of myeloma-related bone disease. |
Genasense
(oblimersen,
Bcl-2
antisense,
G3139)
| Genta, Inc.
| Trials combining Genasense with other regimens in relapse setting.
|
GM-CSF
(Leukine)
| US Oncology | Maintenance therapy post auto transplant for MM
|
GVAX | Cell Genesys, Inc. | Newly diagnosed myeloma patients undergoing transplant. |
INCB018424
(JAK2-inhibitor) | Incyte Corporation | Small molecule Janus kinase inhibitor for patients with rel/ref mm. |
| IPH 2101 | Innate Pharma | Multi-center, open-label trial designed to evaluate IPH2101 as a single agent in patients with stable multiple myeloma after induction therapy. |
ITF2357 | Italfarmaco | Histone deacetylase inhibitor given as monotherapy to patients with relapsed or progressive mm. |
Kineret™
(anakinra) | Amgen | Mayo (Rochester) study of IL-1beta antagonist for smoldering/indolent MM |
KIR-Ligand
Mismatched
Haplo-Identical
Natural Killer
Cells
| Arkansas Cancer Research Center | For relapse after single or tandem transplant and for high-risk multiple meloma. |
KLH vaccine
(keyhole limpet
hemocyanin)
| National Cancer Institute | Low or intermediate risk myeloma patients undergoing autotransplant. |
LBH589
| Novartis
| HDAC inhibitor for patients with relapsed/refractory myeloma who have received at least two prior lines of therapy and whose disease has progressed on the latest therapy. |
mapatumumab
(HGS-ETR1; TRM-1; HGS1012) | Human Genome Sciences | Monoclonal antibody to TRAIL-R1 used in combination with bortezomib in patients with relapsed or refractory myeloma. |
Neotrofin®
(leteprinim
potassium)
| NeoTherapeutics | For treatment of chemotherapy-induced peripheral neuropathy. (Enrollment completed.) |
Neulasta®
(pegfilgrastim,
pegylated
G-CSF)
| Amgen | Pegylated G-CSF (filgrastim) for stem cell mobilization prior to harvest. |
Nexavar®
(BAY 43-9006, sorafenib, sorafenib tosylate)
| Bayer and Onyx Pharmaceuticals
| Oral therapy targeted to receptor tyronsine kinases involved with both tumor cell proliferation and angiogenesis; for patients with relapsed or refractory myeloma.
|
O-6-benzyl-
guanine
| National Cancer Institute and Pacific Pharmaceuticals | Novel chemotherapy for treatment of relapsed myeloma. |
Panzem™
(2-meth-
oxyestradiol,
2ME2)
| EntreMed, Inc. | Antiangiogenesis agent for treatment of relapsing myeloma. |
PD 0332991
| Pfizer
| In combination with Velcade and dexamethasone in patients who have received at least one prior treatment for mm. |
perifosine
(KRX-0401) | Keryx Pharmaceuticals, Inc. | Akt pathway inhibitor known as an alkylphosphocholine. Ph II safety and efficacy trial with perifosine alone and in combination with dexamethasone. |
PI-88 | Progen Industries Limited | Phase II trial of VEGF inhibitor completed in Australia; early planning stages in US. |
Prochymal
| Osiris Therapeutics | For treatment of GVHD (graft versus host disease) following allo transplant.
|
Proleukin®
(IL-2,
Interleukin-2)
| National Cancer Institute and Chiron | For advanced myeloma as part of auto or syngeneic transplant. |
PTK787 | Novartis and Schering, AG | Novel oral angiogenesis inhibitor as post-transplant maintenance following high-dose therapy and autologous SCT. |
PXD101 | CuraGen and TopoTarget A/S | Small molecule histone deacetylase inhibitor for MM patients who have failed at least 2 prior treatment regimens. |
Quadramet®
(EDTMP,
samarium-153
ethylene
diamine
tetramethylene
phosphonate
Samarium)
| Mayo Clinic, Rochester, MN | In combination with standard high-dose chemotherapy for patients undergoing stem cell transplant. |
RAD001
(everolimus)
| Novartis | mTOR (mammalian target of Rapamycin) inhibitor for patients with relapsed/refractory mm.
|
resveratrol
(SRT501) | GlaxoSmithKline | Open-label clinical study to assess the safety and activity of SRT501 with or without concurrent bortezomib administration, when administered once daily in 21-day cycles, in male and female subjects with multiple myeloma. |
Revlimid®
(CC-5013,
lenalidomide)
| Celgene | Various trials in combination with other agents, including bortezomib, thalidomide, cyclophosphamide and dexamethasone for relapsed/refractory mm. |
Rituxan
(rituximab) | Biogen Idec &
Genentech | High-dose cyclophosphamide in combination with rituximab in patients with primary refractory, high-risk, or relapsed myeloma; also being studied for the treatment of peripheral neuropathy in patients with MGUS. |
romidepsin
(depsipeptide, FR901228)
| Gloucester Pharmaceuticals | Novel chemotherapy agent for relapsed/refractory myeloma. |
SCH 727965
| Schering-Plough | Cyclin-dependent kinase inhibitor. |
SCIO-469 | Scios, Inc. | Relapsed, refractory MM |
sorafenib | | See Phase II Nexavar. |
sunitinib (sunitinib malate, Sutent®)
| Pfizer | Multicenter efficacy trial of oral agent previously approved for GIST and kidney cancer. |
Thalomid®*
(thalidomide)
| Celgene Corporation | Used with dexamethasone as induction therapy before, and with prednisone as maintenance therapy after, high-dose therapy with stem cell transplant. |
| Regeneron
| Open-label safety and efficacy study for patients with relapsed or refractory multiple myeloma. |
VELCADE®
(bortezomib,
PS-341, LDP-
341,
MLN-341)
| Millennium Pharmaceuticals, Inc. | |
Xcytrin (motexafin
gadolinium) | Pharmacyclics | Relapsed and refractory myeloma. |
XL999 | Exelixis, Inc. | Potent small molecule inhibitor of recepto tyrosine kinases FGF, VEGF, and PDGF being evaluated in patients with relapsed or refractory mm. |
ZIO-101 | ZIOPHARM, Inc. | Multi-center trial of small-molecule organic arsenic. |
Zolinza
(vorinostat
MK0683) | Merck | An international,. multicenter, open-label study of vorinostat in combination with bortezomib in patients with relapsed or refractory mm. |
